
BioMarin Pharmaceutical Inc.
BMRNHealthcare|Biotechnology|US
$56.03
-0.09 (-0.16%)
DCF Value
$7.43
Tangible Book / Share
$4.20
Cash / Share
$3.80
Financials
Financial Snapshot
Market Cap
$10.85B
Enterprise Value
$14.30B
Revenue (TTM)
$3.66B
Net Income (TTM)
-$19.1M
Cash & Investments
$736.0M
Net Cash
-$3.45B
Free Cash Flow (TTM)
$557.9M
Operating CF (TTM)
$676.6M
Debt/Equity
0.67
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $789.7M | $1.40B | $1.08B | $753.8M | $1.07B | $1.01B | $1.29B | $1.07B | $1.14B | $1.56B | $736.0M | |
| Operating Cash Flow | -$227.8M | -$8.8M | $20.2M | $48.3M | $85.4M | $304.5M | $175.9M | $159.3M | $572.8M | $828.0M | $676.6M | |
| Free Cash Flow | -$376.2M | -$208.0M | -$124.4M | -$96.8M | -$52.2M | $185.3M | $54.9M | $51.6M | $475.4M | $725.0M | $557.9M | |
| Capital Expenditure | -$148.4M | -$199.2M | -$144.6M | -$145.0M | -$137.5M | -$119.2M | -$121.0M | -$107.6M | -$97.4M | -$103.0M | -$118.8M | |
| Financing Cash Flow | $727.1M | $507.1M | -$388.0M | -$74.7M | $181.1M | -$48.0K | -$18.6M | -$18.7M | -$526.4M | -$42.4M | $3.54B |
R&D Spending
R&D (TTM)
$758.7M
R&D Intensity
20.8%
R&D Growth vs Prior
-17.7%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.12B | $1.31B | $1.49B | $1.70B | $1.86B | $1.85B | $2.10B | $2.42B | $2.85B | $3.22B | $3.66B | |
| R&D Expense | $661.9M | $610.8M | $696.3M | $715.0M | $628.1M | $628.8M | $649.6M | $746.8M | $747.2M | $921.9M | $758.7M | |
| R&D % of Revenue | 59.3% | 46.5% | 46.7% | 42.0% | 33.8% | 34.1% | 31.0% | 30.9% | 26.2% | 28.6% | 20.8% | |
| SG&A | $476.6M | $554.3M | $604.4M | $680.9M | $737.7M | $759.4M | $823.2M | $892.4M | $1.01B | $1.28B | $1.79B |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.12B | $1.31B | $1.49B | $1.70B | $1.86B | $1.85B | $2.10B | $2.42B | $2.85B | $3.22B | $3.66B | |
| Cost of Revenue | $209.6M | $241.8M | $315.3M | $359.5M | $524.3M | $470.5M | $503.0M | $532.1M | $580.2M | $736.8M | $898.3M | |
| Gross Profit | $907.2M | $1.07B | $1.18B | $1.34B | $1.34B | $1.38B | $1.59B | $1.89B | $2.27B | $2.48B | $2.76B | |
| R&D | $661.9M | $610.8M | $696.3M | $715.0M | $628.1M | $628.8M | $649.6M | $746.8M | $747.2M | $921.9M | $758.7M | |
| SG&A | $476.6M | $554.3M | $604.4M | $680.9M | $737.7M | $759.4M | $823.2M | $892.4M | $1.01B | $1.28B | $1.79B | |
| Operating Income | -$803.4M | -$14.7M | -$123.5M | -$100.5M | -$43.4M | -$82.3M | $161.0M | $185.8M | $484.2M | $533.5M | $237.9M | |
| Interest Expense | $39.5M | $42.7M | $43.7M | $23.5M | $29.3M | $15.3M | $16.0M | $17.3M | $12.7M | $10.9M | $136.7M | |
| Pretax Income | -$831.0M | -$35.9M | -$142.7M | -$94.8M | -$49.0M | -$75.3M | $149.6M | $188.6M | $541.8M | $482.5M | $43.7M | |
| Net Income | -$630.2M | -$117.0M | -$77.2M | -$23.8M | $854.0M | -$64.1M | $141.6M | $167.6M | $426.9M | $348.9M | -$19.1M | |
| EPS (Diluted) | -3.79 | -0.67 | -0.44 | -0.13 | 4.53 | -0.35 | 0.75 | 0.88 | 2.21 | 1.80 | -0.08 | |
| EBITDA | -$698.0M | $91.0M | -$3.4M | $31.9M | $83.7M | $47.4M | $265.4M | $306.8M | $650.5M | $572.9M | $445.3M | |
| Shares Out. (M) | 166.22 | 174.43 | 177.27 | 179.04 | 191.68 | 182.85 | 188.96 | 191.59 | 196.71 | 197.39 | 193.59 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $408.3M | $598.0M | $494.0M | $437.4M | $649.2M | $587.3M | $724.5M | $755.1M | $942.8M | $1.31B | $736.0M | |
| Short-Term Investments | $381.3M | $797.9M | $590.3M | $316.4M | $416.2M | $426.6M | $567.0M | $318.7M | $194.9M | $248.9M | $0.00 | |
| Total Current Assets | $1.42B | $2.21B | $2.06B | $1.94B | $2.34B | $2.27B | $2.75B | $2.96B | $3.23B | $3.95B | $3.92B | |
| Total Assets | $4.02B | $4.63B | $4.43B | $4.69B | $5.85B | $6.00B | $6.38B | $6.84B | $6.99B | $7.59B | $11.57B | |
| Total Current Liabilities | $439.3M | $816.5M | $523.2M | $932.5M | $492.5M | $546.5M | $588.9M | $1.18B | $607.0M | $759.0M | $1.60B | |
| Long-Term Debt | $660.8M | $813.5M | $830.4M | $486.2M | $1.08B | $1.08B | $1.08B | $593.1M | $595.1M | $597.2M | $3.51B | |
| Total Liabilities | $1.26B | $1.82B | $1.46B | $1.57B | $1.74B | $1.74B | $1.77B | $1.89B | $1.33B | $1.51B | $5.31B | |
| Stockholders' Equity | $2.77B | $2.81B | $2.97B | $3.12B | $4.11B | $4.27B | $4.60B | $4.95B | $5.66B | $6.09B | $6.26B | |
| Retained Earnings | -$1.52B | -$1.64B | -$1.69B | -$1.72B | -$861.6M | -$930.8M | -$789.2M | -$621.6M | -$194.7M | $154.2M | $181.7M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$227.8M | -$8.8M | $20.2M | $48.3M | $85.4M | $304.5M | $175.9M | $159.3M | $572.8M | $828.0M | $676.6M | |
| Capital Expenditure | -$148.4M | -$199.2M | -$144.6M | -$145.0M | -$137.5M | -$119.2M | -$121.0M | -$107.6M | -$97.4M | -$103.0M | -$118.8M | |
| Free Cash Flow | -$376.2M | -$208.0M | -$124.4M | -$96.8M | -$52.2M | $185.3M | $54.9M | $51.6M | $475.4M | $725.0M | $557.9M | |
| Investing Cash Flow | -$484.0M | -$305.5M | $264.4M | -$31.0M | -$53.6M | -$366.3M | -$20.0M | -$111.2M | $136.5M | -$414.2M | -$4.73B | |
| Financing Cash Flow | $727.1M | $507.1M | -$388.0M | -$74.7M | $181.1M | -$48.0K | -$18.6M | -$18.7M | -$526.4M | -$42.4M | $3.54B | |
| Issuance of Stock | $712.9M | $60.9M | $67.5M | $31.6M | $0.00 | $0.00 | $69.3M | $69.4M | $0.00 | $14.5M | $14.4M | |
| Repurchase of Stock | $0.00 | -$33.5M | -$35.9M | $0.00 | -$50.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$42.6M | |
| Net Debt Issuance | $0.00 | $481.7M | -$375.0M | -$5.1M | $203.8M | -$3.0M | -$2.6M | -$2.3M | -$495.0M | $0.00 | $3.63B | |
| Stock Based Comp. | $134.6M | $140.3M | $148.8M | $159.9M | $189.7M | $197.3M | $196.3M | $207.1M | $201.6M | $181.4M | $219.6M | |
| Net Change in Cash | $11.3M | $189.7M | -$104.0M | -$56.5M | $211.7M | -$61.9M | $137.3M | $30.6M | $187.7M | $368.8M | -$514.1M |
Dilution Tracker
Shares Outstanding
194M
5-Year Share Growth
+3.0%
Stock Issuance (TTM)
$14.4M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 166.22 | 174.43 | 177.27 | 179.04 | 191.68 | 182.85 | 188.96 | 191.59 | 196.71 | 197.39 | 193.59 | |
| Change vs Prior % | — | 4.9% | 1.6% | 1.0% | 7.1% | -4.6% | 3.3% | 1.4% | 2.7% | 0.3% | -1.9% | |
| Stock Issuance | $712.9M | $60.9M | $67.5M | $31.6M | $0.00 | $0.00 | $69.3M | $69.4M | $0.00 | $14.5M | $14.4M | |
| Stock Repurchase | $0.00 | -$33.5M | -$35.9M | $0.00 | -$50.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$42.6M | |
| Stock Based Comp. | $134.6M | $140.3M | $148.8M | $159.9M | $189.7M | $197.3M | $196.3M | $207.1M | $201.6M | $181.4M | $219.6M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 81.2% | 81.6% | 78.9% | 78.9% | 71.8% | 74.5% | 76.0% | 78.0% | 79.7% | 77.1% | 75.4% | |
| Operating Margin % | -71.9% | -1.1% | -8.3% | -5.9% | -2.3% | -4.5% | 7.7% | 7.7% | 17.0% | 16.6% | 6.5% | |
| Net Margin % | -56.4% | -8.9% | -5.2% | -1.4% | 45.9% | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% | -0.5% | |
| EBITDA Margin % | -62.5% | 6.9% | -0.2% | 1.9% | 4.5% | 2.6% | 12.7% | 12.7% | 22.8% | 17.8% | 12.2% | |
| FCF Margin % | -33.7% | -15.8% | -8.3% | -5.7% | -2.8% | 10.0% | 2.6% | 2.1% | 16.7% | 22.5% | 15.3% | |
| ROE % | -22.8% | -4.2% | -2.6% | -0.8% | 20.8% | -1.5% | 3.1% | 3.4% | 7.5% | 5.7% | -0.3% | |
| ROA % | -15.7% | -2.5% | -1.7% | -0.5% | 14.6% | -1.1% | 2.2% | 2.5% | 6.1% | 4.6% | -0.2% | |
| ROIC % | -16.9% | -0.4% | -1.7% | -0.6% | 14.1% | -1.3% | 2.6% | 2.7% | 6.0% | 5.6% | -1.0% | |
| R&D / Revenue % | 59.3% | 46.5% | 46.7% | 42.0% | 33.8% | 34.1% | 31.0% | 30.9% | 26.2% | 28.6% | 20.8% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.5% | 17.6% | 13.5% | 14.3% | 9.2% | -0.8% | 13.5% | 15.4% | 18.0% | 12.9% | |
| Gross Profit | 23.0% | 18.1% | 9.7% | 14.3% | -0.6% | 3.0% | 15.8% | 18.5% | 20.5% | 9.3% | |
| Operating Income | -625.8% | 98.2% | -740.3% | 18.7% | 56.8% | -89.6% | 295.5% | 15.4% | 160.6% | 10.2% | |
| Net Income | -266.8% | 81.4% | 34.0% | 69.1% | 3681.1% | -107.5% | 320.9% | 18.4% | 154.6% | -18.3% | |
| EPS (Diluted) | -254.2% | 82.3% | 34.3% | 70.5% | 3584.6% | -107.7% | 314.3% | 17.3% | 151.1% | -18.6% | |
| Operating Cash Flow | -2.8% | 96.2% | 330.8% | 138.8% | 76.9% | 256.7% | -42.2% | -9.5% | 259.7% | 44.5% | |
| Free Cash Flow | 16.3% | 44.7% | 40.2% | 22.2% | 46.1% | 455.3% | -70.4% | -6.0% | 820.5% | 52.5% | |
| R&D Expense | 4.3% | -7.7% | 14.0% | 2.7% | -12.2% | 0.1% | 3.3% | 15.0% | 0.1% | 23.4% | |
| SG&A Expense | 18.5% | 16.3% | 9.0% | 12.7% | 8.3% | 2.9% | 8.4% | 8.4% | 13.1% | 26.6% | |
| Total Assets | 7.9% | 15.1% | -4.4% | 5.9% | 24.7% | 2.7% | 6.2% | 7.3% | 2.2% | 8.7% | |
| Book Value / Share | 11.1% | -3.4% | 4.1% | 4.0% | 30.2% | 2.7% | 6.5% | 6.1% | 12.9% | 6.6% | |
| Debt | 3.2% | 71.9% | -29.3% | 3.4% | 26.6% | 0.2% | 0.4% | 0.2% | -40.7% | -1.0% | |
| Diluted Shares | 3.9% | 4.9% | 1.6% | 1.0% | 7.1% | -4.6% | 3.3% | 1.4% | 2.7% | 0.3% |
Valuation
P/E (TTM)At Loss
10Y Low / Med / High18.46 / 32.65 / 136.17
P/S2.97
10Y Low / Med / High3.54 / 8.88 / 12.31
P/B1.73
10Y Low / Med / High1.87 / 4.17 / 5.54
EV/EBITDA32.12
10Y Low / Med / High18.73 / 177.32 / 487.47
EV/Revenue3.91
10Y Low / Med / High3.33 / 9.13 / 12.56
P/FCF19.44
10Y Low / Med / High15.72 / 87.18 / 350.66
Intrinsic Value Models (per share)
DCF Value
$7.43
Tangible Book / Share
$4.20
Cash / Share
$3.80
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -21.80 | -133.09 | -193.52 | -650.38 | 18.46 | -252.43 | 136.17 | 108.34 | 29.21 | 32.65 | -622.56 | |
| P/S Ratio | 12.31 | 11.84 | 10.11 | 8.88 | 8.52 | 8.75 | 9.15 | 7.49 | 4.38 | 3.54 | 2.97 | |
| P/B Ratio | 4.97 | 5.54 | 5.08 | 4.85 | 3.86 | 3.79 | 4.17 | 3.66 | 2.21 | 1.87 | 1.73 | |
| EV/EBITDA | -20.09 | 177.32 | -4573.64 | 487.47 | 194.76 | 351.17 | 73.64 | 60.15 | 18.75 | 18.73 | 32.12 | |
| EV/Revenue | 12.56 | 12.28 | 10.34 | 9.13 | 8.76 | 9.02 | 9.32 | 7.63 | 4.27 | 3.33 | 3.91 |
Analyst Estimates & Quality
Altman Z-Score
1.85
Grey Zone
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $3.87B | $4.45B | $4.83B |
| Net Income | $589.7M | $1.24B | $1.52B |
| EPS | $3.00 | $6.36 | $7.68 |
| # Analysts (EPS) | 15 | 15 | 12 |
Revenue Segments
By Product
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Royalty And Other | $54.6M | $62.8M | $54.0M | $46.7M | $44.5M | $53.5M |
| Product | — | $1.78B | $2.04B | $2.37B | $2.81B | $3.17B |
| Enzyme Product | — | — | — | $1.72B | — | — |
By Geography
| Segment | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|
| Europe | $178.7M | $252.6M | $301.5M | $436.4M | $509.2M | $518.5M |
| Latin America | $142.3M | $147.5M | $182.4M | $185.0M | $218.8M | $205.9M |
| Rest Of World | $124.8M | $209.2M | $241.5M | $172.9M | $197.6M | $223.8M |
| U S | $444.1M | — | — | — | — | — |
| UNITED STATES | — | $507.5M | $588.2M | $696.8M | $778.4M | $912.4M |